RxDoctor Payments Data

Eileen Lydon

Adult Health · New York, NYNPI 1699945220

Payments from drug & device makers

$8,910in general payments, 2019–2025

Across 36 payments — averaging $247.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$3K
  • AstraZeneca$3K
  • Novartis$2K
  • Amgen$951
  • Sanofi$386
  • Pfizer$118
$6,563in research payments, 2019–2025

Across 1 payment — averaging $6563.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$7K

What the payments were for

  • Consulting fees$5,13558%
  • Speaking & faculty fees$3864%
  • Travel & lodging$2,02823%
  • Food & beverage$1,36115%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.8$2,785
AstraZeneca(2 entities)8$2,550
Novartis13$2,120
Amgen5$951
Sanofi1$386
Pfizer1$118

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,910 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$22,560
Medicare patients
183
Services billed
256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ForteoTeriparatide12$46,482
Alendronate Sodium45$1,666
MethotrexateMethotrexate Sodium57$1,145
Raloxifene Hcl34$624
Celecoxib11$361
Leflunomide12$351
Sulfasalazine18$174
Prednisone23$78
Vitamin D2Ergocalciferol (Vitamin D2)13$40

Paid to pharmacies, not to this prescriber.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →